

**If you have been diagnosed with cancer and will be having surgery, your tumor can be sent to Oncotech for this special testing by your surgeon.**

The Extreme Drug Resistance Assay requires living viable tumor cells to perform the assay. A specimen that is paraffin embedded, fixed, minced, or frozen cannot be used. In addition, patients must not have had chemotherapy or radiation therapy within 3 weeks of specimen collection. The assay can also be performed on other samples containing cancer cells, such as malignant fluids, for example.

If you or someone you know is a potential candidate for chemotherapy treatment for cancer, the physician must order the test immediately following surgery. The decision to order the test is usually made prior to surgery so that the appropriate specimen handling materials can be ordered from Oncotech in advance to ensure availability at the time of surgery.

**Over 80,000 cancer patients have had their tumors tested by the EDR Assay.**

If you have questions about the Extreme Drug Resistance (EDR®) Assay, you can visit the Oncotech website at [www.oncotech.com](http://www.oncotech.com) for further information. Representatives are also available in every region of the United States to answer your physician's questions, or to facilitate the ordering of the test. For additional information on ordering Oncotech services, please have your doctor call Oncotech Client Services at (800) 662-6832 for assistance.

### Billing Policies

Oncotech bills insurance directly and does not balance bill the patient. Patients may be responsible for co-payments or unmet deductible amounts where required by law or insurance contract.

Oncotech has negotiated reimbursement contracts with many of the country's leading insurance carriers, including many managed care organizations. Call your insurance carrier for specific coverage guidelines.

The Medicare system has determined that Extreme Drug Resistance Assays are "part of the generally accepted medical practice" and are "not experimental." Oncotech bills Medicare directly.

Oncotech will assist patients in obtaining payment for test and may provide indigent care where appropriate.

### HIPAA Policies

Oncotech Inc. is committed to proper Health Insurance Portability and Accountability Act (HIPAA) compliance. We have adopted procedures and protocols for adequate management and security of protected health information provided to us by clients and business associates. We are also committed to vigilant monitoring of ongoing legislative changes for continued updating of these policies and procedures as needed. (See Patient's Rights on our website).



Oncotech Inc.  
15501 Red Hill Avenue  
Tustin, CA 92780  
(800) 576-6326  
[www.oncotech.com](http://www.oncotech.com)

## *Important Information for Patients about Choosing a Chemotherapy Regimen*



*Advanced technology makes it possible  
to design a chemotherapy regimen  
specific to the patients needs.*

**The Oncotech  
EDR® Assay**



**The EDR Assay provides information that can be critical to your care, by identifying chemotherapy drugs that are unlikely to be effective.**


The Extreme Drug Resistance (EDR®) Assay is an advanced laboratory test for cancer, also known as a "chemotherapy drug resistance test." This laboratory test is performed by growing a portion of the cancer tumor in the presence of different chemotherapy drugs. If the cancer cells are still able to grow in the presence of a very high (extreme) exposure to a chemotherapy drug, studies have shown that the cancer is unlikely to respond to that drug in the patient's body. The test results are usually released to the treating physician within 7 days of specimen receipt, so that the physician can select the best chemotherapy regimen for the patient, without wasting valuable treatment time.

By eliminating inactive drugs from the therapy regimen, use of the EDR Assay can help avoid exposing patients to the toxicity of those drugs that are unlikely to be effective in treating the tumor and can help to improve the quality of life of the cancer patient during treatment.

EDR Assay results have been widely published in scientific literature and have been shown to be 99% accurate in clinical trials.<sup>1</sup> More recent articles have demonstrated a direct relationship between EDR Assay results and patient survival.<sup>2,3,4</sup> An extensive bibliography, is available for downloading at [www.oncotech.com](http://www.oncotech.com). EDR Assay results can be used within standard treatment guidelines for any cancer type.

Please speak to your physician about this valuable service and visit [www.oncotech.com](http://www.oncotech.com) for further information.

*An ovarian cancer patient's report shows her tumor's resistance to two chemotherapy drugs (red bars). In this case, she can be prescribed an alternate regimen, which may increase her chances of receiving a more effective chemotherapy at the beginning of her treatment.*



## Extreme Drug Resistance Assay Features and Benefits Summary

EDR Test	Test Benefits	Cost of the Test	Ordering the Test	For Additional Info
Immediately after surgery, specimen sent to Oncotech	Over 99% accurate in identifying ineffective drugs	Oncotech bills insurance companies directly	Speak to your doctor to see if the EDR test is right for you	Visit the Oncotech website at <a href="http://www.oncotech.com">www.oncotech.com</a>
Specimen tested using EDR Assay Technology	Avoids direct cost of ineffective therapies and related morbidity	Patients may be responsible for co-payments	Your physician can directly order the Oncotech assay	Call Oncotech at (800) 576-6326 for more information
Results indicate "resistant" drugs	Spares patients unnecessary toxicity	Oncotech does not balance bill the patient	Representative are available to assist in the ordering process	Send us an email request at <a href="mailto:support@oncotech.com">support@oncotech.com</a>
Physician use results to plan the most effective chemotherapy regimen	Saves valuable treatment time	Oncotech has reimbursement contracts with many leading insurance carriers	Saves valuable treatment time and test results available in 7 days	

<sup>1</sup> Weisenthal et al., Highly Specific Prediction of Antineoplastic Drug Resistance with an In Vitro Assay Using Suprapharmacologic Drug Exposures. J Natl Cancer Inst 82:582-588, 1990.

<sup>2</sup> Mehta et al., Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer and Treatment 68:225-237, 2001.

<sup>3</sup> Holloway et al., Association Between In Vitro Platinum Resistance in the EDR Assay and Clinical Outcome for Ovarian Cancer Patients. Gynecologic Oncology, Vol 87:1, 8-16, 2002.

<sup>4</sup> Lolzzi et al., Survival Outcomes in Patients With Recurrent Ovarian Cancer Who Were Treated With Chemoresistance Assay-Guided Chemotherapy. Am J Obstet Gynecol 189:5, 1301- 1307, 2003.